Anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Capabilities in Combination Product Development Globally

The market for combination drug-device products is expected to surpass $250 billion globally by 2030, as parenterally-delivered biologic products and therapies represent an increasingly large share of the overall biopharmaceutical market. To serve this growing demand, pharmaceutical manufacturers are seeking specialized regulatory and technical development expertise necessary to successfully bring these combination products to market.

Founded in 2014, German-based anteris medical and Swiss-based anteris helvetia (together, "anteris") specialize in supporting the development and commercialization of injectable combination products, medical devices, and in-vitro diagnostic products. These capabilities made it the ideal acquisition for US-based Kymanox, a life science solutions partner who offers comprehensive end-to-end solutions to address challenges in early development, commercialization, and post-market for combination products, biologics, pharmaceuticals, and medical devices. The resulting transaction helps both companies realize their shared goals of geographic expansion, while also bolstering service capabilities by providing a broader array of highly specialized services. By combining the regulatory expertise from both companies, clients will be able to truly benefit from this synergy to ensure compliance and submission excellence to FDA, EMA and Notified Bodies.

Crosstree's deep expertise in the global pharma development sector and cross-border transaction experience helped anteris find the ideal partner to achieve its goal of international growth.

Crosstree helps clients develop and execute growth strategies that maximize synergies for all stakeholders.

ABOUT ANTERIS

Founded in 2014 (anteris medical) and 2018 (anteris helvetia), the joint anteris team supports the pharmaceutical, biotech, and medical device industries globally by managing the development, quality, and registration of (drug/device and biologic/device) combination products, medical devices, and in-vitro diagnostic products. Product registration pathways for the EU market supported by anteris include authorization under the centralized procedure, Notified Body Opinions, CE-marking (all classes), and for the US market, applications under the 505(j), 505(b)(2), or 351(k) pathways. Anteris supports customers in more than a dozen countries within and outside of Europe. Learn more at www.anteris-medical.com.

ABOUT KYMANOX

Kymanox is a life science professional services organization that offers engineering, scientific, project management, quality, human factors, testing / QC, CQV and regulatory support to companies exclusively in the biotechnology, pharmaceutical, medical device, and combination product industries. With its diverse team of experts, Kymanox helps clients navigate commercialization challenges that arise throughout a product's life cycle – from early development to post-market – with optimized safety, quality, efficacy, and accessibility. Kymanox was founded in 2004 and is headquartered in Morrisville, North Carolina USA. Kymanox is backed by WestView Capital Partners, a Boston-based growth equity firm. Learn more at www.kymanox.com.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

Crosstree's proven track record of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.

JASON LAYTON
Director
jason.layton@crosstreecapital.com
813-578-7109